

# Accurate and comprehensive evaluation of O6-methylguanine-DNA methyltransferase promoter methylation by nanopore sequencing

Skarphedinn Halldorsson<sup>1</sup>  | Richard Mark Nagymihaly<sup>1</sup> | Areeba Patel<sup>2,3</sup> |  
Petter Brandal<sup>4,5</sup> | Ioannis Panagopoulos<sup>4</sup> | Henning Leske<sup>6,7</sup> |  
Marius Lund-Iversen<sup>5</sup> | Felix Sahn<sup>2,3</sup>  | Einar O. Vik-Mo<sup>1,8</sup>

<sup>1</sup>Vilhelm Magnus Laboratory, Institute for Surgical Research, Department of Neurosurgery, Oslo University Hospital, Oslo, Norway

<sup>2</sup>Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany

<sup>3</sup>CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

<sup>4</sup>Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

<sup>5</sup>Department of Oncology, Oslo University Hospital, Oslo, Norway

<sup>6</sup>Department of Pathology, Oslo University Hospital, Oslo, Norway

<sup>7</sup>University of Oslo, Oslo, Norway

<sup>8</sup>Institute for Clinical Medicine, University of Oslo, Oslo, Norway

## Correspondence

Skarphedinn Halldorsson, Vilhelm Magnus Laboratory, Institute for Surgical Research, Department of Neurosurgery, Oslo University Hospital, Oslo, Norway.  
Email: skarphedinn.halldorsson@rr-research.no

## Funding information

Regional Health Authorities, Grant/Award Numbers: 2017073, 2021039, 2023059

## Abstract

**Aims:** The methylation status of the O6-methylguanine-DNA methyltransferase (*MGMT*) promoter region is essential in evaluating the prognosis and predicting the drug response in patients with glioblastoma. In this study, we evaluated the utility of using nanopore long-read sequencing as a method for assessing methylation levels throughout the *MGMT* CpG-island, compared its performance to established techniques and demonstrated its clinical applicability.

**Methods:** We analysed 165 samples from CNS tumours, focusing on the *MGMT* CpG-island using nanopore sequencing. Oxford Nanopore Technologies (ONT) MinION and PromethION flow cells were employed for single sample or barcoded assays, guided by a CRISPR/Cas9 protocol, adaptive sampling or as part of a whole genome sequencing assay. Methylation data obtained through nanopore sequencing were compared to results obtained via pyrosequencing and methylation bead arrays. Hierarchical clustering was applied to nanopore sequencing data for patient stratification.

**Results:** Nanopore sequencing displayed a strong correlation ( $R^2 = 0.91$ ) with pyrosequencing results for the four CpGs of *MGMT* analysed by both methods. The *MGMT*-STP27 algorithm's classification was effectively reproduced using nanopore data. Unsupervised hierarchical clustering revealed distinct patterns in methylated and unmethylated samples, providing comparable survival prediction capabilities. Nanopore sequencing yielded high-confidence results in a rapid timeframe, typically within hours of sequencing, and extended the analysis to all 98 CpGs of the *MGMT* CpG-island.

**Conclusions:** This study presents nanopore sequencing as a valid and efficient method for determining *MGMT* promoter methylation status. It offers a comprehensive view of the *MGMT* promoter methylation landscape, which enables the identification of potentially clinically relevant subgroups of patients. Further exploration of the clinical implications of patient stratification using nanopore sequencing of *MGMT* is warranted.

## KEYWORDS

CRISPR/Cas9, glioblastoma, *MGMT* promoter methylation, Nanopore sequencing

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2024 The Authors. *Neuropathology and Applied Neurobiology* published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

## INTRODUCTION

Glioblastoma (GBM), IDHwt is the most common aggressive primary malignant brain tumour in adults [1] with a median survival of about 15 months [2]. Standard treatment for GBM involves surgical resection followed by a combination of radiation and chemotherapy. The frequently used chemotherapeutic drug temozolomide (TMZ) is an alkylating agent that induces methylation of O-6 guanidine residues in dividing cells, leading to DNA damage and apoptosis [3]. Although often well tolerated, TMZ can cause a range of side effects. TMZ is therefore suggested to be limited to patients who are likely to benefit from it and withheld from patients who most likely will experience side effects without improvement in survival [4]. The alkylating effects of TMZ are countered by the DNA repair protein O-6-methylguanine-DNA methyltransferase (MGMT). Methylation of the MGMT promoter is believed to silence its expression, thereby increasing the sensitivity of GBM tumour cells to TMZ [5]. The presence of MGMT promoter methylation has been associated with increased survival in GBM patients treated with temozolomide and radiation therapy [6]. MGMT promoter methylation status is therefore an important factor for the management and treatment of GBM [7].

Various methods are utilised to directly measure or estimate MGMT promoter methylation, including methylation-specific PCR, pyrosequencing, Sanger sequencing or methylation bead array [8, 9]. All these methods rely on bisulfite conversion of native DNA and PCR amplification prior to analysis and only include a subset of the 98 CpG sites in the CpG-island of MGMT [10] (Figure 1A). For example, the Qiagen MGMT pyrosequencing kit, which is widely used in the clinical setting, detects methylation on 4 CpG sites (76–79) in the MGMT CpG island. In addition, there is neither a clear consensus on the best cut-off values for the classification of clinically relevant methylated or unmethylated samples nor on the optimal method to use [14]. In recent years, advances in sequencing technology have enabled more sensitive and accurate detection of DNA methylation. Nanopore sequencing, which uses a nanopore-based sensor to detect changes in electrical current as nucleic acids (DNA or RNA) pass through a pore, can detect epigenetic modifications, such as methylation, directly from the raw current signal [15]. Due to the long-read nature of nanopore sequencing, it also affords methylation analysis of far longer sequences than methylation-specific PCR, pyrosequencing or methylation bead arrays. Consequently, nanopore sequencing offers an overview of the methylation status of all CpGs of the MGMT CpG-island, using native genomic DNA without bisulfite conversion, which can be both time and cost-efficient in a clinical setting [16]. Recently developed enrichment methods such as nanopore Cas9 targeted sequencing (nCats) [17] and adaptive sampling (AS) [18] can be used to direct the sequencing effort to specific genomic regions. In this study, we compared the results of nanopore sequencing of the MGMT promoter region of 165 samples from central nervous system (CNS) tumours, including 103 GBMs, with results obtained from standard diagnostic methods such as pyrosequencing or Illumina 850 K bead array.


### Key points

- Nanopore sequencing can reliably determine MGMT promoter methylation status.
- The analysis is extended to all 98 CpGs of the MGMT CpG-island.
- Nanopore sequencing data identifies distinct methylation patterns, potentially guiding personalized treatment strategies.


## MATERIALS AND METHODS

### Patients and samples


Samples from four independent cohorts were included in this study: (1) retrospective analysis of DNA from 64 CNS tumour samples provided by the Institute for Cancer Genetics and Informatics, Oslo University Hospital, that were screened for MGMT promoter methylation using the Qiagen<sup>®</sup> MGMT pyrosequencing kit (MGMT pyro kit). These samples are referred to as ‘Retrospective nCATs’; (2) retrospective analysis of 67 sequences generated as part of the Rapid-CNS adaptive sampling pipeline [19] analysed by Illumina<sup>®</sup> methylation 850 K bead array. These samples are referred to as ‘Rapid-CNS’; (3) DNA extracted from 16 glioma biopsies from patients operated at Oslo University Hospital. A separate biopsy derived from paraffin-embedded tissue was analysed with the Qiagen<sup>®</sup> MGMT pyrosequencing kit at the Department of Molecular Pathology, Oslo University Hospital. These samples are referred to as ‘Prospective nCATs’; (4) DNA from 18 CNS tumours was extracted and sequenced in total as part of a whole genome sequencing project. These samples are referred to as ‘WGSeq’. Table S1 provides an overview of all samples used in this study. Written, informed consent was obtained from patients at the time of surgery and reviewed by the ethical review board at the respective institutions. Samples were collected through both new and previously published studies and approved according to Regional ethical board numbers S-06046, 2016/1791 and 388359 [19]. In total, 165 samples were analysed for MGMT promoter methylation status, including 103 GBM IDHwt and 28 IDHmut glioma samples. Figure 1B shows the distribution of sample classification and predetermined methylation status. Two methods were used to enrich the region of interest: CRISPR/Cas9-targeted sequencing of the MGMT promoter region [20] and adaptive sampling. Cas9 targeted sequencing was applied to 80 samples, 45 of which were run as single samples and 36 were run as multiplexed groups of five. Sixty-seven samples were previously analysed as part of an adaptive sampling pipeline. The remaining 18 samples were analysed as part of a whole genome sequencing panel.



(A)



(B)



(C)

**FIGURE 1** (A) Schematic overview of the 98 CpG sites of the *MGMT* CpG-island with relevant functional areas including the transcription start site (TSS), minimal promoter and enhancer as defined by Harris et al. [11, 12] as well as the differentially methylated regions (DMR) one and two as described by Malley et al. [10]. The two CpG sites used by the *MGMT*-STP27 classifier [13] and the four CpG sites included in the Qiagen® *MGMT* pyrosequencing kit are shown below. (B) Distribution of diagnosis and known methylation status of the sample cohort. (C) Median methylation coverage of the 98 CpG sites in the *MGMT* promoter region of methylated and unmethylated samples by method of acquisition (adaptive sampling, multiplexed nCats, single sample nCats and whole genome sequencing)

### Sample preparation and nanopore sequencing

Between 10 and 25 mg of fresh/frozen tissue was used to extract genomic DNA (Merck's GenElute™ Mammalian Genomic DNA Mini-prep kit) following the manufacturer's protocol. The purity and concentration of DNA samples were determined using NanoDrop™ One and Qubit™ 4 Fluorometers (Thermo Fischer Scientific).

### nCATs

Cas9-mediated targeted sequencing was performed with the Cas9 Sequencing Kit (Oxford Nanopore Technologies) according to the manufacturer's protocol (version ENR 9084 v109 revR 04Dec2018). Briefly, Cas9 ribonucleoprotein complexes (RNPs) were created by

mixing equimolar concentrations (100 μM) of CRISPR RNA (crRNA) and trans-activating elements (tracrRNA) to HiFi Cas9 enzyme (IDT). Dephosphorylated gDNA (2–5 μg) was cleaved and dA-tailed with Cas9 RNPs and Taq polymerase. Finally, sequencing adaptors were ligated to the cleaved fragments, and the final DNA library was purified with AMPure XP beads (Beckman Coulter). Barcodes were applied to several samples to allow the multiplexing of five samples based on an experimental protocol from Oxford Nanopore Technologies (UNPUBLISHED Cas9 Native Barcoding, version: cas-native-bar-coding-v1-revA). Purified DNA libraries were loaded onto R9.4.1 flow cells on MinION Mk1B or Mk1C devices and sequenced for 4–24 h. Individual flow cells were flushed and re-used up to four times for single samples and twice for multiplexed samples. A minimum pore count of 300 was deemed sufficient for a single sample, and 800 for multiplexed samples.

## Whole genome sequencing

Whole genome sequencing of CNS tumour DNA was performed with the ligation sequencing kit SQK-LSK114 and protocol (version: sqk-lsk114 GDH 9173 v114 revH 10Nov2022 promethion) from ONT. Libraries were loaded onto R10.4.1 PromethION flow cells (one sample per flow cell) and sequenced for 72 h.

## RAPID-CNS

Raw fast5 sequences of all fragments mapping to the *MGMT* promoter in the Rapid-CNS [19] data were provided for re-analysis.

## Primers

All primers were purchased from Integrated DNA Technologies (Leuven, Belgium). Previously published primers were initially used to target the *MGMT* promoter region [20], termed *MGMT*-left-1 (ATGAGGGGCCACTAATTGA) and *MGMT*-right-1 (ACCTGAGTAGCTCCGTAC), yielding a fragment of 2,522 bp. In order to increase *cas9* efficiency and expand the size of the fragment, we added additional crRNA primers: *MGMT*-left-2 (GCCAACCACGTTAGACAATGG), *MGMT*-right-2 (GTACGGAGCTATACTCAGGT), *MGMT*-right3 (CTGGAATCGCATTCCAGTAGTGG) and *MGMT*-right-4 (ACTTCGCAAGCATCACAGGTAGG) resulting in a fragment of 4,800 bp.

## Data analysis

Raw sequences were basecalled, methylation called and mapped (hg38, chromosome 10) using the Guppy toolbox (version 6.4.6) from ONT. Per site methylation values were extracted from modified BAM files and aggregated across forward and reverse strands using the modkit toolbox (version 0.2.2) from ONT. All statistical analyses were performed in R (version 4.2.1). The source code and data to reproduce all analyses and figures from this manuscript are available at Github ([https://github.com/SkabbiVML/MGMT\\_R](https://github.com/SkabbiVML/MGMT_R)).

## RESULTS

### Data acquisition

Sequence depth of the *MGMT* promoter region in the samples varied based on method, sequencing time as well as DNA and flow-cell quality. This is reflected in the per-site valid methylation coverage (methylated bases + canonical bases). Single sample runs produced on average more sequences in the region of interest and higher mean methylation coverage (mean = 69.4, median = 28.1) than barcoded runs (mean = 13.6, median = 10.3) and adaptive sampling

(mean = 12.2, median = 9.8) (Figure 1C). No bias in sequencing depth was observed between methylated and unmethylated samples across *Cas9* targeted or WGSeq samples, either single or multiplexed. However, a statistically significant difference in methylation coverage was observed between methylated (mean = 15.9, median = 16.2) and unmethylated (mean = 10.5, median = 10.6) samples analysed by adaptive sampling ( $p = 0.012$ ). This is likely due to the relatively high number of IDHwt GBM samples among the unmethylated samples (40 of 48, 83%) in comparison to the methylated samples (9 of 21, 43%). IDHwt GBM samples commonly exhibit loss of heterozygosity on chromosome 10 and the *MGMT* gene [21].

### Nanopore sequencing compared to established methods

The *MGMT* pyro kit and the *MGMT*-STP27 classifier are common methods to infer the clinically relevant methylation status of *MGMT*. Both methods rely on a limited number of CpG sites. A subset of our samples ('Retrospective nCATs',  $n = 64$ ) was previously analysed using the Qiagen® *MGMT* pyrosequencing kit (*MGMT* pyro kit), which specifically measures CG methylation on four CpG sites in Chr10:129467253-129467272 (hg38), which corresponds to CpGs 76–79 of the *MGMT* CpG-island. To directly compare the results of nanopore sequencing and the *MGMT* pyro kit, we extracted methylation results for CpGs 76–79 with at least three valid methylation calls per site ( $n = 62$ ) from the nanopore data and compared them to methylation values obtained using the *MGMT* Pyro kit (Figure 2) on the same DNA sample. Pearson's correlation coefficient between the methylation values of each overlapping CpG site between nanopore and pyrosequencing ranged from 0.89 to 0.94 ( $R^2 = 0.79$ – $0.89$ ) (Figure 2a). Results from the *MGMT* pyro kit are typically returned as an average methylation percentage of all four CpGs for classification and clinical decision-making. When results were averaged across all four CpG sites, the correlation increased to 0.95 ( $R^2 = 0.91$ ) (Figure 2B).

An average methylation level of  $\geq 10\%$  using the *MGMT* pyro kit is considered to be methylated [8, 22]. The 'Retrospective nCATs' samples offer a direct comparison between nanopore sequencing and the *MGMT*-pyro kit, as the same DNA was analysed via both methods. To compare classification results, a logistic regression model was trained using the average methylation of CpGs 76–79 based on nanopore sequencing and classification based on the *MGMT* pyro kit as an indicator. An ROC curve of the fitted model showed an AUC of 0.992 (Figure 2C). The optimal methylation percentage by nanopore sequencing to separate methylated and unmethylated samples as classified by *MGMT* pyro kit was 22% methylated (95% confidence intervals <10% and >33% methylated). When this logistic regression model was applied to the remaining samples to predict methylation status, sensitivity and specificity were reduced with an AUC of 0.951. Two of 62 samples (3.2%) in the training set (Retrospective nCATs) and 12 of the 98 remaining samples (12.2%) did not match the known *MGMT* methylation status (Figure 2D).




FIGURE 2 Legend on next page.

**FIGURE 2** Comparison of nanopore sequencing and Qiagen® MGMT pyro kit of CpGs 76–79 in the MGMT CpG-island. Results show the per-site methylation percentage of each CpG (A) or average values of four CpG sites analysed by the MGMT pyro kit (B) in the ‘retrospective nCATs’ samples. The black vertical line marks the 10% cut-off value between methylated and unmethylated samples as measured by the MGMT pyro kit. (C) ROC curves for a logistic regression model based on average methylation of CpGs 76–79 by nanopore sequencing (retrospective nCATs, 60 samples) with classification by the MGMT pyro kit as operator (solid black) and prediction of MGMT status of 98 samples (dashed grey). (D) Comparison of known MGMT status (methylated or unmethylated, x-axis) based on the optimal average methylation threshold of CpGs 76–79 derived from the training samples (retrospective nCATs) and model predictions (other samples). The Y-axis represents the average methylation percentage of CpG sites 76–79 based on nanopore sequencing. The dashed horizontal line represents the optimal threshold of 22% methylated, and the grey box represents 1–95% confidence interval (<10% and >33%).

Illumina® Human Methylation BeadChips (HM-27K, HM-450K and HM-850K) are microarray-based platforms used to investigate DNA methylation patterns in human samples. These platforms only cover a subset of the approximately 30 million CpG sites in the human genome [23]. To predict the clinically relevant methylation status of MGMT, a regression model, MGMT STP27, has previously been developed. This model uses the methylation status of two array probes, cg12434587 and cg12981137, as reported by Bady et al. [13, 24]. These probes correspond to CpG sites 31 and 84 in the MGMT CpG island (Figure 1A).


The samples from the Rapid-CNS study ( $n = 67$ ) were analysed by Illumina® HM-850 K EPIC array in addition to nanopore sequencing, and the ground truth methylation status was derived from the MGMT-STP27 classifier. To compare nanopore sequencing results to the MGMT-STP27 classifier results, the methylation level of the two CpG sites represented in the MGMT-STP27 algorithm was extracted from the nanopore results, and the methylation percentage values were plotted against each other (Figure 3A). The unmethylated samples generally show low methylation on both sites, while methylated samples display a varied degree of methylation on both sites. A multiple logistic regression model based on the methylation percentage of CpG 31 and CpG 84 in the Rapid-CNS data with known status as the indicator was generated. The AUC of the training model was 0.972 (Figure 3B). The model accurately predicted the MGMT known methylation status of 77 of the remaining 97 samples (80%) with an AUC of 0.944 (Figure 3C).

### Clustering based on nanopore sequencing separates methylated and unmethylated samples

To investigate the impact of methylation at all CpG sites within the MGMT CpG island, we compared the average methylation percentage of each CpG site between methylated and unmethylated samples (Figure 4A). These values demonstrated that the biggest differences in methylation levels occur at CpGs 7 through 14 and 72 through 91. Welch's two-sided  $t$  tests between methylated and unmethylated samples were performed at every CpG site, and the results were adjusted for multiple testing (Bonferroni method). Figure 4B shows the adjusted  $p$  values for every site in the MGMT CpG-island. Interestingly, low  $p$  values were observed at CpG sites 4 through 14 (excluding CpG 7), which are far upstream of DMR1 and DMR2 (Figure 1A). Furthermore, 19 CpG sites were found to have lower  $p$  values when comparing methylated and unmethylated samples than the CpG sites included in the MGMT pyro kit (CpGs 76–79) or the MGMT-STP27 classifier (CpGs 31 and 84) Figure 4B.

Unsupervised hierarchical clustering based on all 98 CpG sites of the CpG-island using Ward's method revealed two main clusters that largely correspond to the previously determined classification as MGMT methylated or unmethylated (Figure 4C). Unmethylated samples exhibited low methylation levels throughout the CpG island, except for the first five CpG sites, which were often methylated regardless of the overall methylation status of the sample. In contrast,

**FIGURE 3** Comparison of nanopore sequencing and the *MGMT*-STP27 classifier. (A) Methylation percentage of CpG 31 (probe ID: cg12434587) and CpG 84 (probe ID: cg12981137) in the *MGMT* promoter for 65 samples in the Rapid-CNS cohort (left) and remaining samples (right). Ellipses represent 90% confidence intervals. (B) ROC curves for a logistic regression model based on methylation of CpGs 31 and 84 by nanopore sequencing (Rapid-CNS) with classification by the *MGMT*-STP27 classifier as operator (solid black) and prediction of *MGMT* status of 96 remaining samples (dashed grey). (C) Separation of samples based on the linear predictors extracted from the logistic regression model.




methylated samples showed a larger gradient of methylation, with higher levels of methylation towards either end of the *MGMT* CpG-island.

Clustering based on nanopore sequencing data recategorized nine samples, which have been previously classified as methylated, as otherwise unmethylated samples. In turn, seven previously defined unmethylated samples were recategorized as otherwise methylated samples (Figure 4C).

The read depth of nanopore sequencing typically falls below standard sequencing methods. Therefore, we investigated how sequence read depth impacts sample classification in nanopore sequencing. To assess the influence of decreasing read depth in the *MGMT* CpG-

island on sample classification, we conducted random downsampling of all samples with over 20 reads. A graphical representation of methylation patterns, ranging from 100 reads to 10, 5, or 2 reads (Figure S1A), indicates minimal deviation from the smoothed methylation profile until the read depth drops to only two reads. Subsequently, we reclassified the samples using the *MGMT*-Pyro logistic regression model as described above. Among the 29 samples initially classified as 'unmethylated' based on the full sequence depth, 27 (93%) maintained this classification after downsampling to 10 and 5 reads. Similarly, of the 13 samples initially classified as 'methylated' based on the full sequence depth, 11 (85%) remained stable through downsampling to 5 reads (Figure S1B). To assess the impact of read



**FIGURE 4** (A) Dot plot showing the average methylation percentage of each CpG site in the MGMT CpG island. Error bars represent standard deviation. (B) Dot plot showing Bonferroni adjusted  $p$  values of Welch's two-sided  $t$  test between methylated and unmethylated samples for each CpG site. The grey vertical bar shows the location of CpG sites analysed by the MGMT pyro kit, and asterisks show the location of probes included in the MGMT-STP27 classifier. The horizontal line depicts an adjusted  $p$  value of 0.01. (C) Unsupervised hierarchical clustering of all samples based on nanopore sequencing of 98 CpG sites of the MGMT CpG-island ( $n = 165$ )

depth on hierarchical clustering based on methylation values of all CpG sites in the MGMT promoter CpG-island, we assigned samples with full or downsampled read depth to the two major clusters

(Figure 4C) using K-nearest neighbour (KNN) regression. All but two samples (95%) retained their initial clustering from full read depth (>20 reads) to five reads in this approach (Figure S1C).

## Survival analysis of GBM patients based on nanopore sequencing

MGMT promoter methylation is mainly relevant in the context of IDHwt GBM patients. When hierarchical clustering was performed with only GBM samples based on methylation in the whole MGMT CpG-island, a pattern of separation between mostly methylated and unmethylated samples was observed (Figure 5A). However, some discrepancies were observed between predetermined MGMT methylation status and clustering by nanopore sequencing. Therefore, we investigated whether clustering by nanopore sequencing was comparable to established methods in predicting patient survival. We performed survival analysis on 27 GBM patients under 75 years of age (11 females, average age 58.4 years and 19 males, average age 60.2 years) undergoing resection followed by radiotherapy in combination with concomitant and adjuvant temozolomide administration. Biopsies were analysed by both MGMT pyro kit and nanopore sequencing (Table 1). Patients were classified as methylated or unmethylated based on the 10% cut-off value by the MGMT pyro kit and by separation into the two major clusters by hierarchical clustering of nanopore sequencing data (Figure 5A).

Kaplan–Meier survival analysis showed a longer median survival for patients who were classified based on the MGMT pyro kit as methylated compared to patients classified as unmethylated (Figure 5B, 23.8 months vs. 20.9 months). However, the difference in survival did not reach statistical significance ( $p = 0.81$ ). When patients were classified according to clustering of nanopore sequencing data, significantly longer survival was observed in ‘Cluster 2’ patients compared to ‘Cluster 1’ patients (Figure 5C, 24.5 months vs. 21.1 months,  $p = 0.0039$ ). Clusters 1 and 2 largely represent unmethylated and methylated patients based on MGMT pyro kit, respectively, with few exceptions.


## DISCUSSION

Ever since MGMT promoter methylation was discovered as a prognostic marker for overall and progression-free survival in GBM [25, 26], there has been an ongoing debate regarding the optimal method and optimal cut-off to determine clinically relevant methylation of the MGMT promoter (Table S2). Methylation-specific PCR, pyrosequencing and methylation bead arrays are commonly used to determine MGMT methylation status, but direct comparison of the results of these methods have been discordant in up to a third of cases [8, 27, 28]. This is likely due to a lack of consensus between CpG sites queried by different methods and different cut-offs applied. A recent meta-analysis including 32 cohorts and 3,474 patients could not draw strong conclusions on the optimal CpG sites to investigate or the optimal cut-off to apply [14]. This underlines the need for thorough method validation by every institution on their own patient cohort. Considerable effort has been put into finding a minimal set of CpG sites within the MGMT CpG island that can best predict MGMT expression and/or patient survival [8, 24, 29–32]. This is partially due

to the necessity to provide simplified assays that fit the short-read framework of bisulfite sequencing techniques. Most, if not all, clinically established methods of MGMT methylation classification, such as methylation-specific PCR, quantitative methylation-specific PCR, MGMT pyro kit or the MGMT SPT27 classifier, rely on the methylation status of a very limited number of CpG sites to predict the methylation status of MGMT. Although these assays have been shown to largely agree on highly methylated or completely unmethylated samples, they are less reliable when it comes to moderately methylated or so-called ‘grey-zone’ samples [33, 34]. The definition of the methylation ‘grey zone’ in the context of MGMT promoter methylation is complicated by the multitude of methods currently in use for classification. The hierarchical clustering of our samples based on nanopore sequencing of the MGMT CpG-island (Figure 4C) indicates the presence of two distinct groups within methylated samples. However, our data lack the necessary statistical power to evaluate differences in patient survival between these clusters. It should be noted that nanopore sequencing data are comparable between platforms and assays; pooling data from future studies will undoubtedly aid in determining the true clinically significant cut-off for patient classification.

Analysis of MGMT methylation by nanopore sequencing has several advantages over conventional techniques. First, nanopore sequencing can detect epigenetic modifications on native DNA, thereby circumventing the need for bisulfite treatment. This saves time and reduces the potential risk of bias introduced by bisulfite treatment and PCR that has been shown to underrepresent densely hydroxymethylated (5hmC) regions [35]. Using native DNA without manipulation or amplification minimises this bias and reduces the risk of bias between sequencing data generated by different laboratories. Second, the long-read nature of nanopore sequencing offers a complete overview of methylation of the region of interest and can be extended in either direction to include the shores and shelves of the CpG-island. Regions outside the DMR2 are neglected by most established assays but have been shown to discriminate the methylation status of MGMT in GBMs [27]. Third, the flexibility of nanopore sequencing makes it possible to incorporate MGMT methylation analysis into assays such as whole genome sequencing, exome sequencing, in silico enrichment (adaptive sampling) or cas9 targeted enrichment, either as single samples or multiplexed. Finally, the up-front cost of nanopore sequencing is low compared to other sequencing techniques and can be established by smaller laboratories or clinics.

In this study, we analysed 165 CNS tumour samples using targeted or whole genome nanopore sequencing and compared the results to those acquired by pyrosequencing and methylation bead arrays. We report a 95% correlation between nanopore sequencing of the four CpG sites analysed by the MGMT-pyro kit and established an optimal cut-off for nanopore sequencing of the same CpG sites to recreate the pyrosequencing results with 97% accuracy. We also recreated sample classification via methylation bead array and the MGMT-STP27 classifier with nanopore sequencing data with 91% accuracy. Thus, nanopore sequencing of the MGMT CpG island can be used to recreate the methylation status classification of either the MGMT pyro kit or methylation bead array and the MGMT-STP27



**FIGURE 5** (A) Heatmap showing unsupervised clustering of all glioblastoma samples based on nanopore sequencing of the *MGMT* promoter ( $n = 103$ ). Kaplan–Meier patient survival curves based on (B) *MGMT* pyro kit classification or (C) hierarchical clustering according to nanopore sequencing ( $n = 27$ ). The dotted lines represent group median survival (pyrosequencing-methylated = 22.5 months, pyrosequencing-unmethylated = 17.9 months, Nanopore-Cluster1 = 20.9 months, Nanopore Cluster2 = 23.0 months).

classifier with reasonable accuracy. In addition, nanopore sequencing allowed the expansion of the area of analysis to include all 98 CpGs of the *MGMT* CpG-island as previously proposed to be critical for *MGMT*

expression [5]. Unsupervised hierarchical clustering of samples based on nanopore methylation data of the *MGMT* CpG-island showed clear separation into groups that largely correspond to methylated and

**TABLE 1** Patients included in survival analysis

Age	Sex	Resection	OS (months)	Status	MGMT status (Pyro)	NP cluster
60	M	GTR	29.26	Dead	Methylated	2
65	M	STR	29.69	Dead	Methylated	2
64	M	STR	25.48	Dead	Methylated	1
58	M	STR	21.60	Dead	Methylated	2
72	F	STR	21.21	Dead	Methylated	2
58	F	STR	13.61	Dead	Methylated	2
66	M	STR	21.96	Dead	Methylated	2
51	M	GTR	12.85	Dead	Methylated	2
58	M	STR	24.50	Dead	Methylated	2
57	F	STR	28.77	Dead	Methylated	2
64	F	STR	8.30	Dead	Methylated	1
52	F	STR	23.00	Dead	Methylated	2
66	F	STR	13.60	Dead	Methylated	2
51	M	GTR	26.00	Dead	Methylated	1
46	F	GTR	26.90	Alive	Methylated	2
60	F	GTR	21.20	Dead	Methylated	1
66	M	GTR	34.40	Dead	Methylated	2
39	F	GTR	26.30	Alive	Methylated	1
29	M	GTR	35.34	Dead	Unmethylated	2
62	F	STR	6.90	Dead	Unmethylated	1
58	M	STR	11.44	Dead	Unmethylated	1
66	F	GTR	14.99	Dead	Unmethylated	1
73	M	STR	20.91	Dead	Unmethylated	1
57	M	GTR	21.90	Dead	Unmethylated	1
52	M	GTR	26.30	Dead	Unmethylated	1
49	M	GTR	9.40	Dead	Unmethylated	1
55	M	GTR	27.70	Alive	Unmethylated	2

unmethylated samples. Finally, we showed that patient survival prediction based on the clustering of nanopore sequencing data was comparable, if not superior, to classification via the MGMT Pyro kit. To the best of our knowledge, this is the first study to examine all 98 CpG sites within the MGMT CpG island in multiple patient biopsies by nanopore sequencing.

The results presented here demonstrate that nanopore sequencing of the MGMT promoter region can largely recreate the results of established bisulfite-dependant methods while providing additional data on the epigenetic regulation of MGMT and may provide novel criteria for patient stratification. Although the sample size is small, our results suggest that classifying patients via nanopore sequencing is as reliable as classification with methods such as the MGMT pyro kit or methylation bead arrays. Unsupervised hierarchical clustering of glioblastoma samples based on nanopore sequencing indicates the presence of one or more sub-groups within the previously defined methylated samples. These groups are defined by both extent and level of methylation. Further studies and larger patient cohorts are needed to elucidate the functional implications of these sub-groups.

The study is not without limitations. Although 165 patients were included for the evaluation of nanopore sequencing as a method to analyse MGMT CpG-island methylation, only 103 samples were from diagnosed GBM patients, and survival data from primary GBM patients were only available for 27 patients. This limited our ability to evaluate survival beyond the major groups. Our data do not include an estimation of tumour-cell content in the biopsies and do not take into account the possibilities of intratumoural heterogeneity for MGMT promoter methylation, which has previously been shown to affect some gliomas [36]. It is also important to note that high-quality genomic DNA from fresh or fresh-frozen tumour tissue is crucial for MGMT methylation analysis via nanopore sequencing. While the clustering of nanopore sequencing data effectively distinguished between methylated and unmethylated samples, notable discordances emerged when compared to results obtained through conventional methods. This discrepancy underscores the existing uncertainties inherent in the current classification of MGMT methylation status and highlights the need for additional investigations. The remarkable granularity of nanopore data offers a promising foundation for refining classification,

especially in borderline cases. Future studies leveraging the nuanced information provided by nanopore sequencing have the potential to enhance the accuracy and reliability of *MGMT* methylation status determination.

We conclude that methylation status evaluation by nanopore sequencing of the *MGMT* CpG island is comparable to established methods while providing considerable additional information. This is true for both *cas9* targeted sequencing of the *MGMT* CpG-island and inclusion of the *MGMT* promoter region into an adaptive sequencing panel or whole genome sequencing. Distinct subgroups within methylated samples were observed via nanopore sequencing although any difference in patient outcome between these clusters has yet to be determined. We provide a framework for how nanopore sequencing can be used to evaluate *MGMT* promoter methylation in the context of established methods (the *MGMT*-Pyro kit and *STP-27* classifier) or based on full sequencing of the *MGMT* promoter CpG-island. We also provide methylation values for the 98 CpG sites in the *MGMT* promoter CpG-island in 165 samples. Institutions and research groups interested in exploring the applicability of nanopore sequencing for *MGMT* methylation are encouraged to download our data and compare our results to their own samples or established methods of *MGMT* methylation detection.

#### AUTHOR CONTRIBUTIONS

Skarphedinn Halldorsson, Einar O. Vik-Mo, Ioannis Panagopoulos, Petter Brandal and Henning Leske designed the study. Richard Mark Nagymihaly performed DNA extraction, prepared *Cas9* targeted libraries and performed nanopore sequencing. Areeba Patel and Felix Sahm extracted *MGMT* sequences from a panel of adaptive sequencing runs. Skarphedinn Halldorsson and Areeba Patel performed all post-run analyses. Marius Lund-Iversen and Ioannis Panagopoulos performed pyrosequencing of the *MGMT* promoter. Skarphedinn Halldorsson produced all the figures. Skarphedinn Halldorsson, Richard Mark Nagymihaly, Henning Leske and Einar O. Vik-Mo wrote the first draft of the manuscript. All authors contributed to the final manuscript.

#### ACKNOWLEDGEMENTS

The authors would like to thank the patients who participated in this study and their families. We also thank Dr. Thidathip Wongsurawat for sharing her knowledge on *Cas9* targeted sequencing and primer sequences. This project was funded through generous grants from the Regional Health Authorities HSØ Nos. 2017073, 2021039 and 2023059.

#### CONFLICT OF INTEREST STATEMENT

The authors declare no competing interests. The Editors of *Neuropathology and Applied Neurobiology* are committed to peer-review integrity and upholding the highest standards of review. As such, this article was peer-reviewed by independent, anonymous expert referees and the authors (FS) had no role in either the editorial decision or the handling of the paper.

#### PEER REVIEW

The peer review history for this article is available at <https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/nan.12984>.

#### DATA AVAILABILITY STATEMENT

All relevant data to reproduce the analysis in this publication are provided at Github ([https://github.com/SkabbiVML/MGMT\\_R](https://github.com/SkabbiVML/MGMT_R)). Raw, unprocessed sequences are available upon reasonable request from the corresponding authors.

#### ETHICS STATEMENT

Samples were collected and approved according to Regional Ethical Board, numbers S-06046, 2016/1791, and 388359.

#### ORCID

Skarphedinn Halldorsson  <https://orcid.org/0000-0003-4337-9252>

Felix Sahm  <https://orcid.org/0000-0001-5441-1962>

#### REFERENCES

- Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. *Neuro.-Oncol.* 2020;22(Supplement\_1):IV1-IV96.
- Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial. *JAMA - J. Am. Med. Assoc.* 2017;318(23).
- Zhang J, Stevens FGM, Bradshaw TD. Temozolomide: mechanisms of action, repair and resistance. *Curr. Mol. Pharmacol.* 2011;5(1).
- Hegi ME, Ichimura K. *MGMT* testing always worth an emotion. *Neuro.-Oncol.* 2021;23(9):1417.
- Nakagawachi T, Soejima H, Urano T, et al. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (*MGMT*) gene expression in human cancer. *Oncogene.* 2003;22(55):8835-8844. doi:10.1038/sj.onc.1207183
- Hegi ME, Genbrugge E, Gorlia T, et al. *MGMT* promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials. *Clin. Cancer Res.* 2019;25(6):1809-1816. doi:10.1158/1078-0432.CCR-18-3181
- Christmann M, Verbeek B, Roos WP, Kaina B. O6-Methylguanine-DNA methyltransferase (*MGMT*) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. *Biochim. Biophys. Acta (BBA) - Rev. Cancer.* 2011;1816(2):179-190.
- Johannessen LE, Brandal P, Myklebust T, Heim S, Micci F, Panagopoulos I. *MGMT* gene promoter methylation status—assessment of two pyrosequencing kits and three methylation-specific PCR methods for their predictive capacity in glioblastomas. *Cancer Genom. Proteom.* 2018;15(6):437-446.
- Sahm F, Brandner S, Bertero L, et al. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. *Neuro.-Oncol.* 2023.
- Malley DS, Hamoudi RA, Kocalkowski S, Pearson DM, Collins VP, Ichimura K. A distinct region of the *MGMT* CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. *Acta Neuropathol.* 2011;121(5):651-661. doi:10.1007/s00401-011-0803-5

11. Harris LC, Potter PM, Tano K, Shiota S, Mitra S, Brent TP. Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene. *Nucleic Acids Res.* 1991;19(22):6163-6167. doi:10.1093/nar/19.22.6163
12. Harris LC, Remack JS, Brent TP. Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene. *Nucleic Acids Res.* 1994;22(22):4614-4619. doi:10.1093/nar/22.22.4614
13. Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMPstatus. *Acta Neuropathol.* 2012;124:547-560.
14. Brandner S, McAleenan A, Kelly C, et al. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane systematic review. *Neuro.-Oncol.* 2021;23(9):1457-1469.
15. Jain M, Olsen HE, Paten B, Akeson M. The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community. *Genome Biol.* 2016;17(1):239. doi:10.1186/s13059-016-1103-0
16. Laver T, Harrison J, O'Neill PA, et al. Assessing the performance of the Oxford Nanopore technologies MinION. *Biomol. Detect. Quantif.* 2015;3:1-8.
17. Gilpatrick T, Lee I, Graham JE, et al. Targeted nanopore sequencing with Cas9-guided adapter ligation. *Nat. Biotechnol.* 2020;38(4):433-438.
18. Payne A, Holmes N, Clarke T, Munro R, Debebe B, Loose M. Nanopore adaptive sequencing for mixed samples, whole exome capture and targeted panels. *bioRxiv* (2020).
19. Patel A, Dogan H, Payne A, et al. Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. *Acta Neuropathol.* 2022;143(5):609-612.
20. Wongsurawat T, Jenjaroenpun P, de Loose A, et al. A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma. *Acta Neuropathol. Commun.* 2020;8(1):1-13.
21. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathol.* 2015;129(1).
22. Quillien V, Lavenu A, Ducray F, et al. Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. *Cancer Biomark.* 2017;20(4):4-441. doi:10.3233/CBM-170191
23. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. *Nature.* 2001;409(6822).
24. Bady P, Delorenzi M, Hegi ME. Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors. *J. Mol. Diagn.* 2016;18:3.
25. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N. Engl. J. Med.* 2005;352(10):997-1003. doi:10.1056/NEJMoa043331
26. Dovek L, Nguyen NT, Ozer BH, et al. Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. *Neuro.-Oncol. Pract.* 2019;6(3):194-202. doi:10.1093/nop/npy028
27. Tierling S, Jürgens-Wemheuer WM, Leismann A, et al. Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics. *Clin. Epigenetics.* 2022;14(1):26. doi:10.1186/s13148-022-01244-4
28. Håvik AB, Brandal P, Honne H, et al. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. *J. Transl. Med.* 2012;10(1).
29. Brigladori G, Foca F, Dall'Agata M, et al. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. *J. Neurooncol.* 2016;128(2):2-339. doi:10.1007/s11060-016-2116-y
30. Radke J, Koch A, Pritsch F, et al. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients. *Acta Neuropathol. Commun.* 2019;7(1):1. doi:10.1186/s40478-019-0745-z
31. Siller S, Lauseker M, Karschnia P, et al. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. *Acta Neuropathol. Commun.* 2021;9(1):35. doi:10.1186/s40478-021-01134-5
32. Leske H, Camenisch Gross U, Hofer S, et al. MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value. *Acta Neuropathol. Commun.* 2023;11(1).
33. Torre M, Wen PY, Iorgulescu JB. The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients. *Neuro.-Oncol. Pract.* 2022;24(Supplement\_7):vii10. doi:10.1093/neuonc/noac209.039
34. Pinson H, Hallaert G, van der Meulen J, et al. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. *J. Neurooncol.* 2020;146(1):55-62. doi:10.1007/s11060-019-03334-5
35. Huang Y, Pastor WA, Shen Y, Tahiliani M, Liu DR, Rao A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. *PLoS ONE.* 2010;5(1).
36. Wenger A, Vega SF, Kling T, Bontell TO, Jakola AS, Carén H. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. *Neuro.-Oncol.* 2019;21(5):616.

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Halldorsson S, Nagymihaly RM, Patel A, et al. Accurate and comprehensive evaluation of O6-methylguanine-DNA methyltransferase promoter methylation by nanopore sequencing. *Neuropathol Appl Neurobiol.* 2024; 50(3):e12984. doi:10.1111/nan.12984